Diffusion et gestion de communiqués de presse
... a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis 03 avr. 2023 07h00 HE , Source:. FibroGen, Inc. ...
Diffusion et gestion de communiqués de presse
Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis ("IPF") on track to start before year end 2023; Interim ... Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis ("IPF") 27 nov. 2023 08h35 HE , Source:. GRI Bio, Inc. ... Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (" ...
Pulmocide Announces Expansion of Management Team
Aspergillus infection also plays an important role in severe asthma and cystic fibrosis and has been correlated with poorer ... cystic fibrosis, severe asthma, allergic bronchopulmonary aspergillosis, chronic pulmonary obstructive disease, severe flu, and ...
Savara Reports Third Quarter 2018 Financial Results and
The Investigational New Drug application for Molgradex in cystic fibrosis (CF)-affected individuals with chronic NTM lung ... and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; ...
Morphic Announces Corporate Highlights and Financial
... fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using ...
Morphic to Present at 2023 RBC Capital Markets Global
... fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using ...
Press Release Distribution and Management
33% of patients treated with efruxifermin (EFX) (4 of 12) improved by one fibrosis stage without worsening of NASH -- -- 25% of ...
Anthera Pharmaceuticals Has Reached Enrollment Target in
... and exocrine pancreatic insufficiency due to cystic fibrosis. Additional information on the Company can be found at www.anthera ...
Savara Provides Update on IMPALA and AVAIL Pivotal Clinical
... lung infection in people living with cystic fibrosis (CF). With 143 people currently enrolled, out of a target of 200, Savara ... and in preparation for Phase 2a development in cystic fibrosis (CF) affected individuals with chronic NTM lung infection; and ... lung infection in people living with cystic fibrosis (CF). AVAIL will enroll approximately 200 subjects (150 ≤ 21 years old, 50 ...
Telehealth Market Worth USD 559.52 Billion at 25.2% CAGR;
Cystic Fibrosis Market Share & Covid-19 Impact Analysis, By Drug Class (Cystic Fibrosis Transmembrane Conductance Regulator ( ...
Algernon Announces Patients Requested Ongoing Supply
... for idiopathic pulmonary fibrosis ("IPF") and chronic cough, being conducted in Australia and New Zealand, have requested ...
Bellerophon Announces First Patient Enrolled in Phase 2b
... including patients with idiopathic pulmonary fibrosis (PH-IPF). A total of 40 subjects will be enrolled in this clinical trial ...
Pen Needles Market Size to Reach USD 8.91 Billion by 2030,
Liver Fibrosis Market * Disposable Urine Bags Market * Custom Antibody Market * Anticonvulsants Market ...
iBio Adds Biotherapeutic Product for Treatment of Fibrosis
... to Its Proprietary Product Pipeline Latest Addition to Growing ... About Systemic Sclerosis and Idiopathic Pulmonary Fibrosis. Systemic sclerosis is a disorder that affects connective tissue of ... Feghali-Bostwick demonstrates that certain endostatin-derived peptides are useful for both inhibition and reversal of fibrosis ... "Our findings to date suggest that certain endostatin-derived peptides are effective in different mouse models of fibrosis and ...
Press Release Distribution and Management
... fibrosis April 13, 2023 01:15 ET , Source:. Jeito Capital ...
AI Drug Discovery Company Insilico Medicine Offers Free
Insilico Medicine delivers breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, ... including two drugs for idiopathic pulmonary fibrosis and COVID-19 currently in clinical trials. ...